Heart attack patients with rare artery condition may benefit from new blood thinner combo

NCT ID NCT07511257

First seen May 07, 2026 · Last updated May 07, 2026

Summary

This study tests whether adding a blood thinner (rivaroxaban) to a single antiplatelet drug (clopidogrel) works better than the standard two antiplatelet drugs (aspirin plus clopidogrel) for people with acute coronary syndrome and a condition called coronary artery ectasia, where the heart arteries are abnormally widened. About 326 adults hospitalized after a heart attack will be randomly assigned to one of the two treatments and followed for up to a year. The goal is to see if the new combination reduces major heart problems like another heart attack or need for repeat procedures, without causing more dangerous bleeding.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Instituto Nacional de Cardiologia "Ignacio Chávez"

    RECRUITING

    Mexico City, Tlalpan, 14080, Mexico

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.